BVd or BPd for functional high-risk MM: subgroup data from DREAMM-7 & DREAMM-8

In this video, Prof Vania Hungria, hematologist at the Clinica São Germano in São Paulo (Brazil) summarizes the results from a subgroup analysis of the phase III DREAMM-7 and DREAMM-8 studies, evaluating belantamab mafodotin–based combinations in patients with relapsed or refractory multiple myeloma (RRMM). The analysis focused on patients treated after one prior line of therapy, including those with functional high-risk (FHR) disease, defined as progression within 18 months after an autologous stem cell transplantation or initiation of first-line therapy.

In DREAMM-7, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated significant progression-free survival (PFS) and overall survival benefits compared with daratumumab-based standard of care (DVd). Among patients with one prior line of therapy, median PFS was 36.6 months with BVd vs. 19.1 months with DVd. In the FHR subgroup, median PFS was 28.4 months vs. 13.4 months, respectively.

In DREAMM-8, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) also showed substantial efficacy. Median PFS was not reached with BPd compared with 18.5 months with PVd in patients after one prior line of therapy. Among FHR patients, the median PFS was not reached with BPd, while it was reported at 14.8 months with PVd.

Deeper and more durable responses were consistently observed with belantamab-based regimens. In DREAMM-7, median duration of response reached 35.6 months with BVd vs. 22.8 months with DVd, including sustained benefit in functional high-risk patients (32.4 vs. 21.4 months). In DREAMM-8, the median duration of response was not reached with BPd as compared to 18 months with PVd (not reached vs. 13.8 months in FHR patients)

As such, these data support belantamab mafodotin–based combinations as effective options for patients in first relapse, including patients with functional high-risk disease.